The Trade

Spruce Biosciences trades at cash plus $16 million of enterprise value. For that $16M, you get the only active clinical program for a fatal pediatric disease with zero approved therapies, zero competition, and a Priority Review Voucher that recent buyers have paid $200M+ for. The voucher is worth more than twice the company.

The market prices roughly 6% probability of approval. We estimate 40%. And in fifteen days, Denali Therapeutics goes to its PDUFA date with the exact same class of biomarker surrogate endpoint — resolving the single most important open question in the SPRB thesis without Spruce lifting a finger.

The Company

Spruce Biosciences is a post-failure pivot. Tildacerfont for congenital adrenal hyperplasia missed Phase 2b endpoints in late 2024. Stock cratered 97%. They cut 55% of the workforce. The 8-K filed March 20, 2026 includes the tombstone: mutual termination of the Kaken Japan collaboration, forfeiting $65M in milestones. That drug is dead.

What rose from the wreckage is TA-ERT (tralesinidase alfa), an enzyme replacement therapy for Sanfilippo Syndrome Type B (MPS IIIB) acquired in April 2025. It delivers recombinant human NAGLU directly into the brain via intracerebroventricular injection — an Ommaya reservoir surgically implanted in the skull of pediatric patients. Invasive, complex, and the only thing that has ever shown efficacy in this disease. There are roughly 700 patients worldwide. Every competitor is dead: Abeona discontinued their MPS IIIB gene therapy, Lysogene liquidated, Ultragenyx and Denali are working on different subtypes and years behind. If approved, Spruce gets 7-year orphan exclusivity in a market where everyone else has already left.

The Regulatory Path

This is where the thesis lives or dies.

FDA has given TA-ERT every designation it can: Breakthrough Therapy (October 2025), Fast Track, Orphan Drug, Rare Pediatric Disease. In February 2026, Spruce held Type B meetings where the agency confirmed CSF heparan sulfate non-reducing end (HS-NRE) "could potentially serve as an adequate and well-controlled study" for accelerated approval. They validated the surrogate endpoint.

This happened AFTER the FDA rejected REGENXBIO's use of a similar biomarker (CSF heparan sulfate D2S6) for MPS II gene therapy. FDA explicitly said D2S6 "lacks support from published literature" and was "proposed without external expert or scientific consensus." Weeks later, they told Spruce that HS-NRE was acceptable. The FDA is distinguishing between the two assays. The market hasn't fully processed this.

BLA submission targets Q4 2026. Five-year data on 22 patients shows rapid and durable HS reduction with preserved cognitive outcomes versus natural history.

Fifteen Days

Denali Therapeutics has a PDUFA date of April 5, 2026 for tividenofusp alfa in MPS II. Denali's BLA uses the same biomarker class: CSF heparan sulfate as an accelerated approval surrogate. RGNX's CEO said on their Q4 call that they "see them as the same" — the Denali decision and the broader biomarker question.

If FDA approves Denali, the HS biomarker is established as an acceptable surrogate for MPS accelerated approval. Spruce's entire regulatory strategy is validated by someone else's PDUFA date.

Our prediction: 85% probability of Denali approval. Basis: 100% historical approval rate for lysosomal storage ERT BLAs (15/15), FDA-agreed surrogate, Breakthrough Therapy, no AdCom, Royalty Pharma committed $200M conditional on approval by June 30. Denali is a $3.2B company with 18 analysts. Spruce is $80M with 4. The April 5 coverage will focus on DNLI. Almost none of it will mention SPRB.

The cross-ticker implication has to be synthesized, not reported. That's the edge.

The Voucher

If TA-ERT is approved, Spruce receives a Rare Pediatric Disease Priority Review Voucher — a transferable instrument that lets a large pharma company skip the FDA review queue. The program was reauthorized through September 2029. Recent auction prices:

The commonly cited range ($100-150M) is stale by a year. Current market: $200M+.

At $200M, the voucher alone represents $146 per share on 1.37M shares outstanding. Current price: $58.40. The probability-weighted PRV at our 40% P(approval) is $58.40 — the entire stock price, just from the coupon. The drug value is on top.

This is the structurally bizarre part of the setup. The voucher — a regulatory side-effect, not the drug itself — is the dominant value driver. Most models either miss this or use stale pricing.

The Mispricing

Two-state model:

Not approved: stock -> cash ≈$47/share
Approved: stock -> ≈$250/share (PRV + drug NPV + cash)

$58.40 = P(approval) x $250 + (1 - P) x $47
P(approval) = 5.6%

The market is pricing 6%. We estimate 40%. Even at half our confidence — 23% — the stock is worth $94 (+60%).

Four things create the gap. First, screens as catastrophe — down 97%, every quant screen says "failed biotech." The company that exists today is different from the one that broke. Second, undercovered — $80M market cap, four analysts, institutional mandates too small. Third, the DNLI read-through isn't framed as a SPRB event, because nobody covers both names. Fourth, PRV pricing is stale — the jump from $160M to $200M+ happened in six months and most models haven't updated.

The insiders see it. CEO Szwarcberg bought $795K of stock on the open market between October and December 2025 at $58-80. President Gharib bought $320K. Director Ways bought $73K. Total: $1.19M in personal money at roughly the current price. When the CEO of a micro-cap biotech puts $800K of his own cash into the stock during a post-failure rebuild, he's not sending a governance signal. He's making a bet.

The Bear Case

I'm going to take this seriously because the downside is real and there's no options market to hedge.

The dataset is thin. 22 patients for a BLA. BioMarin's Brineura was approved for CLN2 with 24 patients and ICV delivery — but Brineura used a clinical endpoint (motor rating scale), not a biomarker surrogate. No ICV ERT has ever been approved via accelerated approval on a substrate biomarker. Spruce is attempting something with precedent in form but not in mechanism.

FDA biomarker skepticism is real, not hypothetical. RGNX CRL in February 2026. Ultragenyx CEO Kakkis: FDA is "more resistant to the biomarkers than had been agreed upon at the Reagan-Udall meeting." Spruce's Type B guidance is encouraging, not binding. FDA can change position at formal review.

The financing gap is coming. Cash runs to early 2027. BLA Q4 2026, PDUFA mid-2027 at earliest. There will be a dilutive raise (75% probability). At $80+ it's manageable. At $40 it's painful. ICV delivery also caps the commercial ceiling — brain surgery in pediatric patients requires specialized centers and limits penetration.

11.7% short interest. Someone with conviction disagrees.

The honest synthesis: this is a single-point-of-failure thesis. FDA biomarker acceptance is the root node. If it resolves bullish, everything cascades — dataset risk drops, PRV becomes probable, financing gets easier, monopoly compounds value. If bearish, correlated collapse. There is one question. DNLI answers it in fifteen days. Then Spruce answers it again at BLA.

Scenarios

EV: $92 (+57%). Conditional on DNLI approved (85%): EV $103 (+75%). Conditional on DNLI CRL'd (15%): EV $53 (-9%).

Entry: starter pre-DNLI. Cash floor at $47 bounds downside to ≈20%. Add post-DNLI approval on the pullback, not the gap. Do not buy a DNLI CRL dip — wait for FDA to clarify whether HS-NRE is independent of the broader biomarker pushback.

65% of the thesis sits in factors where we have unusual insight (FDA cross-ticker read-through + stale PRV consensus). The remaining 35% is execution and financing risk we can't assess from outside.

Conviction

This is a doorway state — 60/40 on the fundamental thesis. Both patterns fit the evidence. The catalyst chain is building: DNLI in fifteen days, BLA in nine months, PDUFA in fifteen months.

The trade is not "SPRB will be approved." The trade is: the market prices 6% and the evidence supports 40%, the voucher is worth 2.5x the company at prices nobody has updated to, and someone else resolves the biggest open question in two weeks for free.

At $58.40, you're buying cash plus $16M for a monopoly in a fatal disease, a $200M voucher on approval, full FDA designation stack, and management buying alongside you with their own money. The binary is real.

Evidence